WTAP Antibody [E21M11]

Catalog No.: F8500

Application: Reactivity: Human, Monkey

Lane 1: MOLT4, Lane 2: COS-7

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IP1:100

Application
WB, IP

Source
Rabbit Monoclonal Antibody

Reactivity
Human, Monkey

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
55 kDa

Datasheet & SDS

生物学的記述

Specificity
WTAP Antibody [E21M11] detects endogenous levels of total WTAP protein.

Clone
E21M11

Synonym(s)
Pre-mRNA-splicing regulator WTAP; Wilms tumor 1-associating protein; WTAP

Background
Wilms’ tumor 1‑associating protein (WTAP) is a nuclear regulatory subunit of the N6‑methyladenosine (m6A) methyltransferase complex that partners with the catalytic METTL3 and METTL14 subunits to control m6A deposition on a broad spectrum of coding and noncoding RNAs. WTAP contains a conserved domain that mediates interaction with METTL3 and METTL14, and it lacks intrinsic catalytic methyltransferase activity yet provides essential scaffolding that promotes the localization and stabilization of the METTL3–METTL14 complex in nuclear speckles, which are dynamic compartments enriched in splicing and mRNA‑processing factors, thereby coupling m6A modification to cotranscriptional RNA processing. WTAP modulates the efficiency of site‑specific m6A methylation on target mRNAs, which in turn influences pre‑mRNA splicing, polyadenylation, export, stability, and translation by recruiting or competing with m6A readers such as YTHDF and other RNA‑binding proteins, and it contributes to the regulation of key physiological programs, including circadian rhythms, stem‑cell renewal, and developmental gene expression. WTAP is overexpressed and its upregulation sustains elevated m6A modification of oncogenic transcripts that drive proliferation, migration, invasion, and therapy resistance, and WTAP‑dependent restructuring of the m6A epitranscriptome has been linked to enhanced cell‑migration and invasive phenotypes in glioblastoma, cholangiocarcinoma, and other malignancies.

Background

Wilms’ tumor 1‑associating protein (WTAP) is a nuclear regulatory subunit of the N6‑methyladenosine (m6A) methyltransferase complex that partners with the catalytic METTL3 and METTL14 subunits to control m6A deposition on a broad spectrum of coding and noncoding RNAs. WTAP contains a conserved domain that mediates interaction with METTL3 and METTL14, and it lacks intrinsic catalytic methyltransferase activity yet provides essential scaffolding that promotes the localization and stabilization of the METTL3–METTL14 complex in nuclear speckles, which are dynamic compartments enriched in splicing and mRNA‑processing factors, thereby coupling m6A modification to cotranscriptional RNA processing. WTAP modulates the efficiency of site‑specific m6A methylation on target mRNAs, which in turn influences pre‑mRNA splicing, polyadenylation, export, stability, and translation by recruiting or competing with m6A readers such as YTHDF and other RNA‑binding proteins, and it contributes to the regulation of key physiological programs, including circadian rhythms, stem‑cell renewal, and developmental gene expression. WTAP is overexpressed and its upregulation sustains elevated m6A modification of oncogenic transcripts that drive proliferation, migration, invasion, and therapy resistance, and WTAP‑dependent restructuring of the m6A epitranscriptome has been linked to enhanced cell‑migration and invasive phenotypes in glioblastoma, cholangiocarcinoma, and other malignancies.

References
[1] Huang Q, et al. Cell Death Dis. 2022 Oct 7;13(10):852. [2] Cao D, et al. Am J Cancer Res. 2025 Aug 25;15(8):3661-3677.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%